Washington Hospital Center, Georgetown University School of Medicine, Washington, DC 20010, USA.
J Vasc Surg. 2011 Sep;54(3):e1-31. doi: 10.1016/j.jvs.2011.07.031.
Management of carotid bifurcation stenosis is a cornerstone of stroke prevention and has been the subject of extensive clinical investigation, including multiple controlled randomized trials. The appropriate treatment of patients with carotid bifurcation disease is of major interest to the community of vascular surgeons. In 2008, the Society for Vascular Surgery published guidelines for treatment of carotid artery disease. At the time, only one randomized trial, comparing carotid endarterectomy (CEA) and carotid stenting (CAS), had been published. Since that publication, four major randomized trials comparing CEA and CAS have been published, and the role of medical management has been re-emphasized. The current publication updates and expands the 2008 guidelines with specific emphasis on six areas: imaging in identification and characterization of carotid stenosis, medical therapy (as stand-alone management and also in conjunction with intervention in patients with carotid bifurcation stenosis), risk stratification to select patients for appropriate interventional management (CEA or CAS), technical standards for performing CEA and CAS, the relative roles of CEA and CAS, and management of unusual conditions associated with extracranial carotid pathology. Recommendations are made using the GRADE (Grades of Recommendation Assessment, Development and Evaluation) system, as has been done with other Society for Vascular Surgery guideline documents.[corrected] The perioperative risk of stroke and death in asymptomatic patients must be <3% to ensure benefit for the patient. CAS should be reserved for symptomatic patients with stenosis of 50% to 99% at high risk for CEA for anatomic or medical reasons. CAS is not recommended for asymptomatic patients at this time. Asymptomatic patients at high risk for intervention or with <3 years life expectancy should be considered for medical management as the first-line therapy.
颈动脉分叉狭窄的管理是预防中风的基石,也是广泛临床研究的主题,包括多项对照随机试验。颈动脉分叉疾病患者的适当治疗是血管外科医生关注的焦点。2008 年,血管外科学会发布了颈动脉疾病治疗指南。当时,只有一项比较颈动脉内膜切除术(CEA)和颈动脉支架置入术(CAS)的随机试验已经发表。自该出版物发表以来,四项比较 CEA 和 CAS 的主要随机试验已经发表,药物治疗的作用再次得到强调。本出版物更新并扩展了 2008 年的指南,特别强调了六个方面:颈动脉狭窄的识别和特征的影像学检查、药物治疗(作为单独管理,也与颈动脉分叉狭窄患者的干预相结合)、风险分层以选择适合介入管理(CEA 或 CAS)的患者、CEA 和 CAS 的技术标准、CEA 和 CAS 的相对作用以及与颅外颈动脉病变相关的不常见情况的管理。建议使用 GRADE(推荐评估、制定和评价等级)系统做出,这与其他血管外科学会指南文件相同。[已纠正]无症状患者围手术期中风和死亡的风险必须<3%,以确保患者受益。CAS 应保留给有症状且狭窄程度为 50%至 99%的高危患者,由于解剖或医学原因不适合 CEA。目前不建议对无症状患者进行 CAS。有介入高风险或预期寿命<3 年的无症状高危患者应考虑作为一线治疗进行药物治疗。